SUMMARY Low lumbar CSF concentrations of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in patients with multiple system atrophy attended by autonomic failure (MSA) reflect decreased activity in central dopaminergic and serotonergic pathways. These neurochemical changes are consistent with the neuropathological involvement in MSA and distinguish such patients from those with pure autonomic failure who have normal CSF metabolite levels.
Pure autonomic failure (PAF) is a syndrome of chronic autonomic dysfunction that occurs in the absence of peripheral neuropathy or signs of a central neurological disturbance.' Biochemical and pharmacological evidence supports primary involvement of the peripheral autonomic nervous system in the pathophysiology of the disorder but its underlying aetiology remains to be identified.2 Multiple system atrophy (MSA) encompasses the overlapping syndromes of olivopontocerebellar atrophy (OPCA) and striatonigral degeneration;3 in many patients MSA is attended by autonomic failure that appears to be primarily caused by central nervous system lesions. 4 Monoamine neurotransmitters play an important role in the function of central and peripheral neuronal pathways. Measurement of plasma and urinary levels of neurotransmitters and their metabolites provides an index of peripheral function and metabolism. 5 The relationship between norepinephrine and peripheral sympathetic nervous system activity has been extensively studied using this approach.6 Assessment of central nervous system neurotransmitter metabolism is limited to relatively indirect methods although the metabolite levels in CSF have been correlated with a variety of behavioural and functional characteristics.5' ' Previously, we showed that CSF levels Dopamine and serotonin are neurotransmitters in the extrapyramidal system as well as the central pathways concerned with blood pressure regulation. There The intercept of the linear regression of 5-HIAA on HVA levels in CSF indicates that a portion of 5-HIAA is derived from a source which is independent of HVA. This is not surprising since clearly not all serotonergic neuronal activity is linked to that of dopaminergic neurons. It is perhaps more surprising that among the normal subjects as well as among the whole group of patients including those MSA patients with much diminished CSF levels of HVA and 5-HIAA there is a highly significant correlation between the two amine metabolites. The basis of this correlation is unclear, but several possible mechanisms might serve as the basis for this relationship. A physiological link between the two aminergic systems appears most likely. Since correction of the dopamine deficit by levodopa treatment in two patients did not alter the 5-HIAA level, it appears unlikely that this link is due to dopaminergic regulation of serotonergic function. The remaining possibilities for the normal subjects are that both aminergic systems are regulated by a third or several other systems or that the serotonergic system exerts a strong modulatory effect on the dopaminergic system. In the patients with MSA, this third system could be damaged, or the two aminergic systems similarly involved in the degenerative process. The elevation in HVA following Sinemet(R) indicates that the capacity to increase dopamine turnover may be preserved in MSA and probably accounts for the improvement observed in response to anti-Parkinsonian drugs. Of interest is the finding reported by Williams et al that patients with MSA decrease their CSF levels of HVA in response to bromocriptine. " Thus, it appears that some pre-synaptic mechanisms including dopamine synthesis, release, metabolism and receptor activation may remain functional in MSA.
The normal CSF levels of monoamine neurotransmitters in PAF are consistent with the results of other biochemical and pharmacological investigations that indicate peripheral autonomic involvement. 4 
